Moomoo AI 已提取核心信息
On January 11, 2024, Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of delinquency from Nasdaq for failing to hold an annual meeting of shareholders within twelve months of the end of its fiscal year on December 31, 2022. This non-compliance with Nasdaq Listing Rule 5620(a) has prompted Nasdaq to require Exicure to submit a plan within 45 days to address how it will regain compliance. Exicure has the opportunity to request an extension of up to 180 days, or until June 28, 2024, to meet the listing requirements. The company has expressed its intention to submit a compliance plan and seek the extension.
On January 11, 2024, Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of delinquency from Nasdaq for failing to hold an annual meeting of shareholders within twelve months of the end of its fiscal year on December 31, 2022. This non-compliance with Nasdaq Listing Rule 5620(a) has prompted Nasdaq to require Exicure to submit a plan within 45 days to address how it will regain compliance. Exicure has the opportunity to request an extension of up to 180 days, or until June 28, 2024, to meet the listing requirements. The company has expressed its intention to submit a compliance plan and seek the extension.
2024年1月11日，在纳斯达克股票市场上市的生物技术公司Exicure, Inc. 因未能在2022年12月31日财政年度结束后的十二个月内举行年度股东大会而收到纳斯达克的拖欠通知。这种不遵守纳斯达克上市规则5620（a）的行为促使纳斯达克要求Exicure在45天内提交计划，以解决其如何恢复合规的问题。Exicure有机会申请延长最多180天，或延至2024年6月28日，以满足上市要求。该公司已表示打算提交合规计划并寻求延期。
2024年1月11日，在纳斯达克股票市场上市的生物技术公司Exicure, Inc. 因未能在2022年12月31日财政年度结束后的十二个月内举行年度股东大会而收到纳斯达克的拖欠通知。这种不遵守纳斯达克上市规则5620（a）的行为促使纳斯达克要求Exicure在45天内提交计划，以解决其如何恢复合规的问题。Exicure有机会申请延长最多180天，或延至2024年6月28日，以满足上市要求。该公司已表示打算提交合规计划并寻求延期。
有用
没用